TIM-3 blockade: immune and targeted therapy in DIPG

Trends Mol Med. 2023 Dec 12:S1471-4914(23)00276-9. doi: 10.1016/j.molmed.2023.11.014. Online ahead of print.ABSTRACTDiffuse intrinsic pontine glioma (DIPG) remains intractable to conventional treatments. While targeted therapy and immuno-oncology advances offer hope, few strategies show promising results. In a recent article in Cancer Cell, Ausejo-Mauleon et al. introduce TIM-3 blockade as a potential breakthrough for DIPG treatment by targeting cancer cells and regulating the immune microenvironment simultaneously.PMID:38092623 | DOI:10.1016/j.molmed.2023.11.014
Source: Trends in Molecular Medicine - Category: Molecular Biology Authors: Source Type: research